Michael S Kostapanos
Dr Michael S Kostapanos, MD, PhD, FRCP is an expert in Internal medicine at Addenbrooke's Hospital (United Kingdom). Michael S Kostapanos has authored 98 publications, the most recent in 2022, and is an investigator in 5 clinical trials. SLR score: 309 (community average: 125). How the SLR is computed.
LeadR Profile
Internal medicine
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2006 - 2026
Number : 98
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. PMID 34389859 — lipoproteins, cardiovascular diseases, therapeutics, lipoprotein(a) | Eur J Prev Cardiol | 2021 | 14 |
| Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. PMID 35211246 — diabetes mellitus, glucagon-like peptide 1, dipeptidyl peptidase 4, safety, dipeptidyl-peptidase iv inhibitors, peptide hydrolases, therapeutics, hypoglycemic agents | World J Diabetes | 2022 | 43 |
| Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia. PMID 35200696 — risk, fatty acids, hypertriglyceridemia, therapeutics, lipoprotein lipase, triglycerides, apolipoprotein c-iii | J Cardiovasc Dev Dis | 2022 | 4 |
| Is there a role of lipid-lowering therapies in the management of fatty liver disease? PMID 35126843 — liver diseases, ezetimibe, fibrosis, lipoproteins, non-alcoholic fatty liver disease, liver, alcoholics, cholesterol, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors, fatty liver, peroxisome proliferator-activated receptors | World J Hepatol | 2022 | 21 |
| Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome. PMID 33221921 — submandibular gland, salivary glands, healthy volunteers, rheumatic diseases, fluorodeoxyglucose f18, diagnostic imaging, sjogren's syndrome, radionuclide imaging | Rheumatology (Oxford) | 2021 | 9 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map